| P2093 | author name string | Joseph Chin | |
| | Clarisse R Mazzola | |
| P2860 | cites work | Cancer statistics, 2015 | Q27860576 |
| | A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 |
| | Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy | Q30563774 |
| | Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base | Q30784290 |
| | Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. | Q33394575 |
| | Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 | Q33398722 |
| | Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy | Q33405869 |
| | A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer | Q33409364 |
| | Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma | Q33411581 |
| | Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. | Q33627763 |
| | Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer | Q33874421 |
| | Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer | Q33923405 |
| | Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma | Q33931413 |
| | Cabozantinib in progressive medullary thyroid cancer | Q34185084 |
| | Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial | Q34188703 |
| | Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer | Q34303116 |
| | Ramucirumab: preclinical research and clinical development. | Q34446310 |
| | Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | Q34642136 |
| | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | Q34662482 |
| | Multiple mechanisms mediate resistance to sorafenib in urothelial cancer | Q34685436 |
| | Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder | Q34774912 |
| | Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder | Q34812142 |
| | Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis | Q35291439 |
| | SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma | Q35540039 |
| | EAU guidelines on renal cell carcinoma: 2014 update. | Q35548292 |
| | Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial | Q35576189 |
| | Update on chemotherapy for advanced bladder cancer | Q36157935 |
| | A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen | Q36614243 |
| | Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. | Q36615090 |
| | Pazopanib: a novel multitargeted tyrosine kinase inhibitor | Q36731530 |
| | New molecular targets and novel agents in the treatment of advanced urothelial cancer | Q36768971 |
| | Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting | Q37217466 |
| | The future of tyrosine kinase inhibitors: single agent or combination? | Q37258971 |
| | Anti-angiogenesis approach to genitourinary cancer treatment. | Q37354411 |
| | Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group | Q37415341 |
| | Targeting angiogenesis in bladder cancer | Q37428195 |
| | Angiogenesis as a therapeutic target in urothelial carcinoma | Q37781665 |
| | Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. | Q37859970 |
| | Targeted therapy for advanced urothelial cancer of the bladder: where do we stand? | Q38009901 |
| | Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. | Q38028124 |
| | Sunitinib malate in the treatment of urothelial cancer | Q38159713 |
| | Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review | Q38181169 |
| | Bevacizumab: a review of its use in advanced cancer | Q38260176 |
| | A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 |
| | Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells | Q39120264 |
| | Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer | Q39218592 |
| | Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells | Q39677393 |
| | Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells | Q39755748 |
| | Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens | Q39891466 |
| | Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model | Q39974732 |
| | Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature | Q40270911 |
| | Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium | Q40785644 |
| | Phase II study of sunitinib in patients with metastatic urothelial cancer | Q43168171 |
| | Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05) | Q43718098 |
| | Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer | Q43782584 |
| | Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. | Q44124156 |
| | A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium | Q44951549 |
| | Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design | Q45226462 |
| | Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. | Q45908407 |
| | Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression | Q46439216 |
| | Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer | Q46610841 |
| | Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. | Q51208907 |
| | Circulating tumor cells in early bladder cancer: insight into micrometastatic disease. | Q51742759 |
| | Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. | Q51939874 |
| | Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. | Q53058565 |
| | Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. | Q53236575 |
| | Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. | Q53263269 |
| | Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. | Q53696508 |
| | A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. | Q54364572 |
| | EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. | Q54391399 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 913-927 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Targeting the VEGF pathway in metastatic bladder cancer | |
| P478 | volume | 24 | |